TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity

Diabetes. 2013 Jun;62(6):2048-58. doi: 10.2337/db12-0931. Epub 2013 Jan 24.

Abstract

Genetic and immunological screening for type 1 diabetes has led to the possibility of preventing disease in susceptible individuals. Here, we show that human mesenchymal stem/stromal cells (hMSCs) and tumor necrosis factor-α-stimulated gene 6 (TSG-6), a protein produced by hMSCs in response to signals from injured tissues, delayed the onset of spontaneous autoimmune diabetes in NOD mice by inhibiting insulitis and augmenting regulatory T cells (Tregs) within the pancreas. Importantly, hMSCs with a knockdown of tsg-6 were ineffective at delaying insulitis and the onset of diabetes in mice. TSG-6 inhibited the activation of both T cells and antigen-presenting cells (APCs) in a CD44-dependent manner. Moreover, multiple treatments of TSG-6 rendered APCs more tolerogenic, capable of enhancing Treg generation and delaying diabetes in an adoptive transfer model. Therefore, these results could provide the basis for a novel therapy for the prevention of type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigen-Presenting Cells / metabolism
  • Blotting, Western
  • Cell Adhesion Molecules / metabolism*
  • Diabetes Mellitus, Type 1 / metabolism*
  • Female
  • Humans
  • Immunoprecipitation
  • Mesenchymal Stem Cells / metabolism*
  • Mice
  • Mice, Knockout
  • Real-Time Polymerase Chain Reaction
  • T-Lymphocytes, Regulatory / metabolism
  • Th1 Cells / metabolism*

Substances

  • Cell Adhesion Molecules
  • TNFAIP6 protein, human